Evidence map›Paper›PMID 34769053›Full record

ArticleInternational journal of molecular sciences2021

Kei Kikuchi, Daisuke Kaida

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kei KikuchiSchool of Medicine, University of Toyama, Toyama 930-0194, Japan.
Daisuke KaidaFaculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.
University of Toyama · JP

Funding

Japan Society for the Promotion of Science JP21H02423Takeda Science Foundation N/ATamura Science & Technology Foundation N/A
6 · The paper itself

Abstract

The potent splicing inhibitor spliceostatin A (SSA) inhibits cell cycle progression at the G1 and G2/M phases. We previously reported that upregulation of the p27 cyclin-dependent kinase inhibitor encoded by

Indexed as

Cell Cycle CheckpointsCell Line, TumorCyclin-Dependent Kinase Inhibitor p27Cyclin EDown-RegulationE2F1 Transcription FactorG1 PhaseHeLa CellsHumansOncogene ProteinsPyransRNA, MessengerSpiro CompoundsCCNE1 protein, humanCyclin-Dependent Kinase Inhibitor p27Cyclin EE2F1 protein, humanE2F1 Transcription FactorOncogene ProteinsPyransRNA, MessengerSpiro Compoundsspliceostatin Acell cyclecyclin EE2F1G1 phasepre-mRNA splicingspliceostatin A

Identifiers

PMID34769053
PMCPMC8584075
OpenAlexW3208197364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.